ArticlePCN reports : psychiatry and clinical neurosciences2026
Electroconvulsive therapy in an older patient with recurrent major depressive disorder and a permanent pacemaker: A case report.
Article in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Electroconvulsive therapy (ECT) is highly effective for severe or treatment-resistant major depressive disorder, including in older adults. In patients with permanent pacemakers, however, ECT may be avoided because of concern about device malfunction or arrhythmia. Case Presentation: We report a man in his 80s with recurrent major depressive disorder and a dual-chamber pacemaker for complete atrioventricular block. During the approximately 2 years before admission, the depressive episode achieved only partial remission despite mirtazapine 30 mg/day and trials of duloxetine 60 mg/day and venlafaxine 150 mg/day, then worsened acutely. Vortioxetine was introduced after admission, but severe symptoms persisted. Pre-ECT interrogation confirmed pacemaker dependence with only minimal intrinsic ventricular activity. After multidisciplinary preparation, approximately twice-weekly ECT was initiated using a Thymatron System IV device with initial bitemporal placement; stimulus dosing initially followed the half-age method, beginning at 40% (202 mC) with a brief-pulse stimulus. As seizure induction became difficult, augmentation included hyperventilation, theophylline premedication, switching to right unilateral placement, and ketamine anesthesia. Continuous monitoring and peri-ECT device checks showed stable function; no magnet application or reprogramming was required. The patient received 20 treatments. The 21-item GRID Hamilton Depression Rating Scale (GRID-HAM-D) score improved from 32 before ECT to 2 after the acute course. Mood, anxiety, appetite, and physical strength improved early, followed by more gradual improvement in psychomotor retardation. No clinically significant arrhythmias, pacemaker malfunction, oversensing, pacing inhibition, or serious hemodynamic complications occurred. Conclusion: This case supports the feasibility of carefully planned ECT in selected older patients with permanent pacemakers, provided that multidisciplinary planning and practical device precautions are in place.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.